Adding ‘repurposed’ antiparasitic drug to community-wide campaigns with antimalarial treatment could boost impact by up to 61%. Results are published in The Lancet Infectious Diseases on Wednesday March 28th.A drug commonly used to treat parasitic diseases reveals further potential as a new tool for malaria control. A randomised trial published in The Lancet Infectious Diseases shows that multiple, high doses of ivermectin are well tolerated and able to kill mosquitoes feeding on humans for at least 28 days after treatment. Up to now, the mosquito-killing effects of lower doses of this ‘repurposed’ drug had been short-lived.
What’s more, transmission modelling to predict the potential impact of this approach indicates that pairing high-dose ivermectin with a standard malaria treatment (dihydroartemisinin-piperaquine) in community-wide campaigns, such as mass drug administration, could reduce malaria prevalence by up to 61% more than campaigns with only antimalarials. In areas of low prevalence, where 10% of the population is infected, adding ivermectin could reduce prevalence to <0.1% for more than 6 months.
These results are further evidence of the potential of ivermectin to become a powerful new tool to aid malaria elimination efforts, say the authors.
430.000 deaths a year
In sub-Saharan Africa, the malaria parasite Plasmodium falciparum kills 430,000 people every year— 80% of deaths are in Africa, mostly in children under the age of 5. Resistance to insecticides is rising, and mosquitoes are adapting their behaviour to feeding outdoors to escape the killing effects of insecticide-treated nets and indoor residual spraying.
Discovered 30 years ago, more than 2.5 billion doses of ivermectin have been given across Africa and Latin America to kill parasitic worms, including those that cause river blindness and lymphatic filariasis, and has been shown to be safe. A single dose of 300–400 µg/kg is recommended when these mass drug administrations are done yearly, but ivermectin has safely been used in doses up to 2000 µg/kg.
Previous research has shown that ivermectin, even at very low levels, is toxic to Anopheles mosquitoes that spread malaria. Laboratory studies indicate that mosquitoes die or are too weakened to pass on the malaria parasite if they feed on recently treated individuals. However, earlier research showed that the mosquito-killing effects of standard doses (150-200µg/kg) are less than 7 days.
This randomised trial conducted at the Jaramogi Oginga Odinga Teaching and Referral Hospital in Kisumu, Kenya included 141 adults (aged 18-50 years) with uncomplicated P falciparum malaria. Participants were randomly assigned to receive dihydroartemisinin-piperaquine (DP) plus either 3 days of ivermectin 600 µg/kg per day (47 participants), ivermectin 300 µg/kg per day (48), or placebo (46). The researchers fed the patients’ blood at regular intervals to laboratory-reared Anopheles mosquitoes, and assessed mosquito survival every day for 28 days after feeding. 128 participants (91%) attended a visit 7 days after treatment and were included in the main analysis.
Seven days after treatment, mosquitoes died 4-times faster after being fed blood from participants who received the lower dose ivermectin (300 µg/kg per day) treatment compared to those fed on blood from participants given placebo. This mosquito mortality rate was 6-times higher after treatment with the higher dose of ivermectin (600 µg/kg per day) than placebo. During the two weeks after feeding, 41% of mosquitoes died in the placebo arm, compared to 93% and 97% of mosquitoes killed in the 300 and 600 µg/kg/day arms, respectively. The effect on mosquito mortality remained significantly higher 28 days after treatment with both ivermectin doses compared with placebo.
Ivermectin was well-tolerated at both doses with two serious treatment-related side effects reported—an anaphylactic reaction in the 300 μg/kg/day group, and a transient disruption of the heart's normal electrical activity likely resulting from the antimalarial DP in the 600 μg/kg/day group. The majority of adverse events were mild or moderate, with 5/45 (11%) participants reporting at least one treatment-related adverse event in the 600 µg/kg/day dose group, 2/48 (4%) in the 300 µg/kg/day dose group, and none in the placebo group. The most common reactions were mild, short-lived dose-dependent visual disturbances during drug administration.
Population-level modelling suggests that adding high doses of ivermectin for 3 days to mass drug administration with DP could reduce malaria prevalence by an additional 56% (600 µg/kg/day dose) and 44% (300 µg/kg/day dose) in low transmission areas—enhancing the likelihood of achieving local elimination—and by 61% and 54% respectively in high transmission areas like sub-Saharan Africa.
The authors note several limitations, including that the study only included individuals with symptomatic malaria, so the findings might not be generalisable to mass drug administration campaigns that target the entire population—most of whom are either asymptomatic or uninfected. They also note that standard laboratory-reared mosquitoes known to be sensitive to pyrethroids and other classes of insecticides were used, which might not reflect wild populations. Lastly, they highlight that studies of the safety, tolerability, and efficacy of high doses of the drug will need to be done in children, and as multiple rounds, before its effect on malaria transmission can be assessed in community-wide campaigns.
“This is the first study to show the safety and efficacy of multiple high-doses of ivermectin on mosquito mortality”, says Dr Menno Smit from the Liverpool School of Tropical Medicine, Liverpool, UK, who led the study. “Our results suggest that a 300 µg/kg dose of ivermectin each day for 3 days would provide a good balance between efficacy and tolerability.”
“Despite these encouraging findings, further rigorous safety and efficacy trials in younger age groups are needed before high-dose ivermectin can be administered at scale to assess its impact on malaria transmission and human health”, says Smit. Co-author Teun Bousema (theme Infectious diseases and global health) from Radboud university medical center adds that, “high-dose ivermectin may also have potential applications in other vector-borne diseases transmitted by mosquitoes including Zika virus, dengue, and West Nile fever, as well as insect- and tick-borne disease like sleeping sickness and Lyme disease. Further studies should be done to assess the use of high-dose ivermectin against these insects.”
Writing in a linked Comment, Dr Regina Rabinovich from the Harvard T H Chan School of Public Health, Boston, USA says: “Given the high variability of the vector and the parasite, more than one approach will probably be needed to confront this challenge. Studies to repurpose ivermectin could be completed by 2022 if financed soon, and this would provide a short term option for the field. If ivermectin is effective, new endectocides that could safely provide similar benefits with improved characteristics like longer duration of action, could be developed.”
Anne van Kessel
(024) 30 92373
Related news items
Research with twins sheds light on predisposition to overweight11 October 2018
The genetic predisposition to overweight has a greater effect in a living environment that promotes obesity. This was the conclusion of a study conducted at University College London (UCL). Ellen van Jaarsveld was one of the researchers.read more
Major grant for development of e-health program for cardiac rehabilitation11 October 2018
Maria Hopman is creating an e-health program for cardiac rehabilitation together with a consortium of Danish and Swiss companies. The consortium has been awarded a Eurostars grant of € 1.9 million.read more
Martine Hollander, Saskia de Wildt and Rianne van Boekel have been nominated for the VIVA400 Knappe Koppen11 October 2018
Martine Hollander, Saskia de Wildt and Rianne van Boekel have been nominated for the annual VIVA400 list. They have the chance to be awarded in the category Knappe Koppen. Please vote before 6 November.read more
The European Joint co-fund Programme for Rare Diseases (EJP-RD) approved9 October 2018
Radboudumc participates in the European Joint Programme on Rare Diseases (EJP-RD), which was recently approved by the European Commission.read more
Coach2Move highlighted by ZonMw Health care efficiency research program4 October 2018
On 26 September, ZonMw director Henk Smid handed over the evaluation of the Health care efficiency research program to Bas van den Dungen, Director-General of the Ministry of Health, Welfare and Sport.read more
Best clinical abstract award for Lando Janssen4 October 2018
During the annual John Goldman Conference on Chronic Myeloid Leukemia in Miami, Lando Janssen received the best clinical abstract award for his abstract entitled “Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia”.read more